5+ ITEMS = 10% OFF
EU WAREHOUSE · 24–48H DELIVERY
PLAIN BOX · ZERO BRANDING
PAY THE COURIER · NO CARD NEEDED
FREE SHIPPING OVER €85
5+ ITEMS = 10% OFF
EU WAREHOUSE · 24–48H DELIVERY
PLAIN BOX · ZERO BRANDING
PAY THE COURIER · NO CARD NEEDED
FREE SHIPPING OVER €85
Try a substance, brand, or product name…
Cart 0
€85,00 more for free shipping
No products in the cart.
Injectable Steroids
Pharma Test C 250 mg Pharmacom Labs
Pharmacom Labs
€55,00
In Stock(100 available)
Pharma Test C 250 mg Pharmacom Labs (250 mg) — Manufactured by Pharmacom Labs to exacting pharmaceutical standards, this pharmaceutical-grade injectable compound is formulated f…
100 in stock
5+−10%
10+−15%Best price
Third-Party Lab ReportHPLC verified
CoA available on request — email support@vitalquests.org with the batch code from your vial.
Testosterone Cypionate, Pharmacom Labs, 250 mg. Eight-day ester; once-weekly injection is the typical schedule, twice-weekly for tighter dose control. Interchangeable with enanthate in almost every cycle design. Clinically documented across decades of TRT use.
Key Benefits
Functionally equivalent to testosterone enanthate at the receptor level
Foundation compound for every common stack protocol
Each unit dosed at 250 mg — see Recommended Dosage below for protocol-specific intake
Recommended Dosage
Research dosing: TRT 100–200 mg/week; first cycle 400–500 mg/week; intermediate 500–600 mg/week; advanced 700+ mg/week. Split across 2 injections per week even though once-weekly is pharmacokinetically acceptable — flatter plasma smooths E2 management.
How It Works
Testosterone esterified to cyclopentanepropionic acid. Plasma esterases cleave the ester, releasing free testosterone to bind the AR across muscle, bone, and CNS. Functionally identical to enanthate in biological activity; ester difference affects only release kinetics.
Pharmacokinetics
Plasma half-life approximately 8 days. Once-weekly acceptable but produces a ~2× peak-trough swing; twice-weekly preferred. Steady-state at week 4–6. Clearance slower than enanthate — PCT begins 14 days after last pin.
Potential Side Effects
Standard testosterone side-effect profile: oestrogenic (manageable with AI), androgenic (genotype-dependent), HPTA suppression (universal). Hematocrit rise common above 500 mg/week — pull CBC mid-cycle.
Cycle & Stacking Guide
Cycle base, 12–16 weeks. Stack as with enanthate: deca/anadrol (mass), primobolan/boldenone (lean-gain), trenbolone/masteron (cutting). PCT at day 14 post-last-injection with Clomid 50mg + Nolva 20mg for 4 weeks.
Manufacturer Notes
Pharmacom Labs operates from EU-registered facilities with in-house HPLC verification. Every batch ships with a unique code on the label — scannable at pharmacom-labs.com to confirm authenticity before the vial ever leaves the box.
Storage & Handling
Store upright at 15–25 °C in the original box, protected from light and moisture. Oil-based injectables are shelf-stable for the duration printed on the vial when kept at controlled room temperature. Do not refrigerate — cold thickens the carrier oil and makes drawing/injecting harder. Keep out of reach of children. For research and educational purposes only.
Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.
Mechanism & protocol-relevant pharmacology, reviewed by editorial pharmacology lead
The 7-carbon heptanoate ester of endogenous testosterone. IM depot kinetics: serum peak at 24–48 h post-injection, steady-state reached after 4–5 half-lives (weeks 3–4). Once-weekly administration produces ~200 ng/dL peak-to-trough variance at 200 mg/week; trough suppression on EOD or twice-weekly splits. Aromatises via CYP19A1 at physiological rates — 0.2–0.3% substrate conversion to estradiol. Target serum E2 on protocol: 25–40 pg/mL (sensitive LC-MS/MS). Aggressive AI dosing that suppresses E2 below 20 pg/mL produces the documented side profile of arthralgia, libido loss, lipid degradation, and cognitive fog — iatrogenic hypoestrogenaemia is a bigger problem than measured hyperoestrogenaemia in most protocols. HPTA shutdown is total within 14 days and predictable; recovery timeline post-cessation is 3–6 months with SERM-based PCT, longer without. Haematocrit drift is the most consistent long-run biomarker — 3–5 percentage points per cycle, additive across cycles without donation.
Known trade names:
Delatestryl, Testoviron Depot, Cidoteston
Data sourced from published pharmacological literature and authoritative chemical databases (PubChem, DrugBank, ChEBI). Provided for identification and research reference only.
We use cookies for essential site functionality and — with your consent — for analytics and marketing. You can accept all, reject non-essential, or configure. Privacy Policy
Reviews
There are no reviews yet.